Coya Therapeutics completes enrollment in Phase 2/3 ALSTARS trial of COYA 302 in ALS

By Public Technologies
  • Coya Therapeutics completed enrollment of 120 participants in its Phase 2/3 ALSTARS trial of COYA 302 in ALS.
  • Results have not been presented; topline data from the double-blind treatment phase are expected in early Q2 2027.
  • The study aims to show whether the therapy can slow disease progression in people living with ALS.
  • COYA 302 holds FDA Fast Track status, supporting a faster development and review pathway if the data are positive.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005528519) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.